Antifungal-Chemotherapy Drug Interaction Update
The Food and Drug Administration (FDA) has approved an update to the labeling for Noxafil (posaconazole; Merck) regarding an interaction with vincristine.
Bone and Connective Tissue Cancer
Outcomes of Daratumumab Tx Examined in Relapsed Multiple Myeloma
Daratumumab with bortezomib and dexamethasone is associated with longer progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma, according to a study published in the August 25 issue of the New England Journal of Medicine.
FDA Approves Updated ONJ Warning for Prolia, Xgeva
The Food and Drug Administration (FDA) has approved supplemental Biologics License Applications (sBLA) for Amgen’s Prolia (denosumab) and Xgeva (denosumab).
Receiving Myeloma Immunotherapy Earlier May Have Greater Efficacy
Daratumumab (Darzalex), a recently approved immunotherapy drug for multiple myeloma, can provide better benefits if patients receive it earlier in their treatment, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held in Chicago.
Radiation Benefits Superior for Older Patients With in Soft-Tissue Sarcoma
Older patients with soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, according to research published in Anticancer Research.
Unexpected Derm Diagnosis in Patient Treated with Dabrafenib
In a case report published online February 28 in the Journal of Clinical Pharmacy and Therapeutics, researchers document non-HIV-associated Kaposi sarcoma in a male patient with myasthenia gravis and metastatic melanoma treated with the BRAF inhibitor dabrafenib.
Cancer Deaths Declining by 1.5% a Year in the U.S.
Overall rates of cancer and cancer mortality in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer.
Halaven Gains Expanded Use for Treatment of Liposarcoma
The Food and Drug Administration (FDA) has approved Halaven (eribulin mesylate; Eisai) for the treatment of unresectable or metastatic liposarcoma in patients who have received prior chemotherapy containing an anthracycline.
Pexidartinib Designated Breakthrough Therapy for Rare Tumor
The FDA has granted Breakthrough Therapy designation to pexidartinib (formerly PLX3397; Daiichi Sankyo/Plexxikon) for the treatment of tenosynovial giant cell tumor (TGCT) where surgical removal of the tumor would be associated with potentially worsening functional limitation or severe morbidity.
Yondelis Approved for Advanced Soft Tissue Sarcoma
The Food and Drug Administration (FDA) has approved Yondelis (trabectedin; Janssen) for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.
